These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18027228)

  • 81. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
    Dallas MJ
    J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Two-stage adaptive designs with correlated test statistics.
    Hommel G; Lindig V; Faldum A
    J Biopharm Stat; 2005; 15(4):613-23. PubMed ID: 16022167
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Group sequential and discretized sample size re-estimation designs: a comparison of flexibility.
    Wu X; Cui L
    Stat Med; 2012 Oct; 31(24):2844-57. PubMed ID: 22733405
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

  • 85. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
    Cheng B; Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Flexible design clinical trial methodology in regulatory applications.
    Hung HM; Wang SJ; O'Neill R
    Stat Med; 2011 Jun; 30(13):1519-27. PubMed ID: 21344470
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Many-to-one comparison after sample size reestimation for trials with multiple treatment arms and treatment selection.
    Wang J
    J Biopharm Stat; 2010 Sep; 20(5):927-40. PubMed ID: 20721782
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Use of prior information for Bayesian evaluation of bridging studies.
    Hsiao CF; Hsu YY; Tsou HH; Liu JP
    J Biopharm Stat; 2007; 17(1):109-21. PubMed ID: 17219758
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Sample size adaptation in fixed-dose combination drug trial.
    James Hung HM; Wang SJ
    J Biopharm Stat; 2012; 22(4):679-86. PubMed ID: 22651108
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials.
    Stone A
    Pharm Stat; 2010; 9(2):151-61. PubMed ID: 19771540
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A Bayesian noninferiority approach to evaluation of bridging studies.
    Liu JP; Hsueh H; Hsiao CF
    J Biopharm Stat; 2004 May; 14(2):291-300. PubMed ID: 15206527
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Analysis strategies for adaptive designs with multiple endpoints.
    Chang M; Chow SC
    J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Statistical inference on censored data for targeted clinical trials under enrichment design.
    Chen CF; Lin JR; Liu JP
    Pharm Stat; 2013; 12(3):165-73. PubMed ID: 23606647
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A new futility test approach in clinical interim data monitoring.
    Xue D
    Pharm Stat; 2012; 11(6):468-75. PubMed ID: 23015479
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparison of the spending function method and the Christmas tree correction for group sequential trials.
    Stallard N; Facey KM
    J Biopharm Stat; 1996 Jul; 6(3):361-73. PubMed ID: 8854238
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Multistage test procedure for testing Blackwelder's hypothesis of equivalence.
    Lakshminarayanan MY; Patel HI; Stager WJ
    J Biopharm Stat; 1994 Jul; 4(2):165-71. PubMed ID: 7951272
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Information-based sample size re-estimation in group sequential design for longitudinal trials.
    Zhou J; Adewale A; Shentu Y; Liu J; Anderson K
    Stat Med; 2014 Sep; 33(22):3801-14. PubMed ID: 24797715
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Group sequential methods for cluster randomization trials with binary outcomes.
    Zou GY; Donner A; Klar N
    Clin Trials; 2005; 2(6):479-87. PubMed ID: 16422308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.